Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam for General Anesthesia in Laparoscopic Surgery (Real-world Observational Cohort)
ChiCTR2600128270Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remimazolam in postoperative delirium (POD), postoperative nausea and vomiting (PONV) and postoperative pain, sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: Composite endpoint (successful anesthesia and no delayed emergence). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
postoperative delirium (POD)postoperative nausea and vomiting (PONV)postoperative pain
Beyond the preview
Go deeper on ChiCTR2600128270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128270.